The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Some of the most commonly used medications for osteoporosis can lead to osteonecrosis of the jaw (ONJ), a rare but serious side effect.

If you’re one of the 8 million American women with osteoporosis, your doctor has probably talked to you about treatment options to slow the disease’s progression and keep your bones in tip-top shape.

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years ...

The unprecedented coronavirus disease 2019 (COVID-19) pandemic facilitated the rapid development and subsequent deployment of several novel and highly effective vaccines. However, the role of ...

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include ...

Data suggest a protective association of bisphosphonates against having a kidney stone diagnosis or procedure. Patients receiving bisphosphonates for osteoporosis treatment are less likely to have ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...